Join us October 4 from 9:15 AM to 5 PM ET for a hybrid public meeting on Mitigating Risks from Human Xylazine Exposure.

The Reagan-Udall Foundation for the FDA, in partnership with the U.S. Food and Drug Administration (FDA), is holding a hybrid public meeting entitled “Mitigating Risks from Human Xylazine Exposure”. This hybrid public meeting will explore real-world experiences and scientific evidence on emerging data trends for human xylazine exposure. This meeting also seeks to examine concrete strategies for drug development and clinical research that directly supports the mitigation and reduction of risks associated with human exposure to xylazine. Workshop presentations and discussions will include clinical and scientific experts, community and harm reduction organizations, academic researchers, and federal partners.